SCHEMBL2864907

SCHEMBL2864907

O=C(NCCOc1ccccc1)c1ccc2[nH]nc(-c3cc4ccccc4o3)c2c1

nearest known ligand 0.69

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 5/20 0.69
SMN1; SMN2 Q16637 3/20 0.55
HPGD P15428 2/20 0.55
TSHR P16473 2/20 0.55
NPC1 O15118 5/20 0.51
MAPK3 P27361 2/20 0.49
RAB9A P51151 4/20 0.46
TP53 P04637 1/20 0.46
KDR P35968 1/20 0.46
FLT3 P36888 3/20 0.45
POLB P06746 1/20 0.43
CASP3 P42574 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
RECQL P46063 1/20 0.43
CSNK1D P48730 1/20 0.43
ROCK2 O75116 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8256757 0.90 MAPK1 (0.54) MAPK1SMN1; SMN2MAPK3KDRFLT3
SCHEMBL8258494 0.83 KDM4E (0.51) MAPK1HPGDMAPK3TP53FLT3
SCHEMBL8257907 0.82 KDM4E (0.55) MAPK1HPGDMAPK3FLT3CSNK1D
SCHEMBL8257912 0.81 MAPK1 (0.49) MAPK1MAPK3FLT3CSNK1D
SCHEMBL8268058 0.81 KDM4E (0.52) MAPK1HPGDMAPK3TP53FLT3
SCHEMBL8253993 0.80 CSNK1D (0.54) MAPK1MAPK3KDRFLT3CSNK1D
SCHEMBL2872714 0.80 ITK (0.48) MAPK1SMN1; SMN2NPC1MAPK3RAB9A
SCHEMBL8258574 0.80 MAPK1 (0.49) MAPK1MAPK3KDRCSNK1D
SCHEMBL2861677 0.80 KMT2A (0.51) HPGDTSHRTP53FLT3
SCHEMBL8257894 0.79 FLT3 (0.47) MAPK1HPGDMAPK3FLT3CSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-6982274-B2 1H-indazole compound EISAI CO., LTD. (JP) 2006-01-03 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed
US-20040127538-A1 Novel 1h-indazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 MAPK1 1/4885SMN1; SMN2 4812/4885HPGD 1817/4885
US-20040127538-A1 Novel 1h-indazole compound MAPK1, MAPK14, MAPK3 MAPK1 1/4885SMN1; SMN2 4781/4885HPGD 1866/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 MAPK1 1/4885SMN1; SMN2 4812/4885HPGD 1817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.